Verona Pharma plc is a pharmaceutical company that specializes in developing and commercializing innovative therapies for respiratory diseases. The company’s main focus is on the development of drugs that target the underlying mechanisms of respiratory diseases, such as chronic obstructive pulmonary disease (COPD) and cystic fibrosis. Verona Pharma’s lead product candidate, ensifentrine, is a first-in-class dual inhibitor of the phosphodiesterase 3 and 4 enzymes, which has shown promising results in clinical trials for the treatment of COPD. The company is headquartered in London, UK, and has additional offices in the US. Verona Pharma is committed to improving the lives of patients with respiratory diseases through the development of effective and safe therapies.
